

Application Number 09/663,889

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (Cancelled).

17. (Currently amended) A kit combination for site-specifically transforming cells *in vivo* comprising a catheter and a nucleic acid comprising a gene encoding p21.

18. (Cancelled)

19. (Currently amended) The kit combination of claim 17, wherein the catheter is a double balloon catheter.

20. (Currently amended) The kit combination of claim 17, further comprising a pharmaceutical carrier.

21. (Currently amended) The kit combination of claim 20, wherein the pharmaceutical carrier comprises a nucleic acid.

Application Number 09/663,889

22. (Currently amended) The kit combination of claim 17, wherein the nucleic acid is an expression vector.

23. (Currently amended) The kit combination of claim 22, wherein the expression vector comprises a viral promoter.

24. (Currently amended) The kit combination of claim 23, wherein the viral promoter is a CMV promoter.

25. (Currently amended) The kit combination of claim 23, wherein the viral promoter is a RSV promoter.

26. (Currently amended) The kit combination of claim 17, wherein a viral particle comprises the nucleic acid.

27. (Currently amended) The kit combination of claim 26, wherein the viral particle is an adenovirus particle.

28. (Currently amended) The kit combination of claim 26, wherein the viral particle is a retrovirus particle.

29. (Currently amended) The kit combination of claim 17, further comprising a liposome.

Application Number 09/663,889

30. (Currently amended) The kit combination of claim 29, wherein the liposome comprises the nucleic acid.

31. (Currently amended) The kit combination of claim 17, wherein the nucleic acid comprises a second gene.

32. (Currently amended) The kit combination of claim 31, wherein the second gene encodes HLA-B7, an immunotherapeutic agent, cytokine, or prodrug converting enzyme.

33. (Currently amended) The kit combination of claim 32, wherein the prodrug converting enzyme is thymidine kinase.

34. (Currently amended) The kit combination of claim 31, wherein the gene encoding p21 and the second gene are operatively linked.

35. (Currently amended) The kit combination of claim 34, wherein the gene encoding p21 and the second gene are operatively linked such that they form a fusion protein.

36. (Currently amended) The kit combination of claim 35, wherein the gene encoding the fusion protein is a p21-thymidine kinase fusion protein.

Application Number 09/663,889

37-54. (Cancelled)